Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fecal Microbiota Therapy Versus Standard Therapy in NASH Related Cirrhosis
NCT02721264Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Mar 2016
- Primary completion
- Jun 2018
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Randomised trial of fecal microbiome transplant in Nonalcoholic steatohepatitis (NASH) (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Hepatic Venous Pressure Gradient at 1 year. Status: unknown.
02
Drugs
fecal microbiome transplant
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02721264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02721264.